Mireille Alhouayek Selected Research

N-acylethanolamines

1/2021	N-Acylethanolamine-Hydrolyzing Acid Amidase Inhibition, but Not Fatty Acid Amide Hydrolase Inhibition, Prevents the Development of Experimental Autoimmune Encephalomyelitis in Mice.
1/2020	Effects of orthotopic implantation of rat prostate tumour cells upon components of the N-acylethanolamine and monoacylglycerol signalling systems: an mRNA study.
1/2019	Interferon γ treatment increases endocannabinoid and related N-acylethanolamine levels in T84 human colon carcinoma cells.
1/2018	N-acylethanolamine hydrolyzing acid amidase inhibition: tools and potential therapeutic opportunities.
5/2017	N-acylethanolamine-hydrolyzing acid amidase and fatty acid amide hydrolase inhibition differentially affect N-acylethanolamine levels and macrophage activation.
2/2015	N-Acylethanolamine-hydrolyzing acid amidase inhibition increases colon N-palmitoylethanolamine levels and counteracts murine colitis.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Mireille Alhouayek Research Topics

Disease

24	Inflammation (Inflammations) 01/2022 - 08/2011
8	Colitis 02/2019 - 08/2011
7	Inflammatory Bowel Diseases (Inflammatory Bowel Disease) 01/2021 - 10/2012
6	Pain (Aches) 01/2021 - 03/2014
3	Prostatic Neoplasms (Prostate Cancer) 01/2020 - 01/2017
3	Neuroblastoma 01/2019 - 11/2017
3	Obesity 12/2018 - 03/2015
2	Pneumonia (Pneumonitis) 01/2021 - 01/2019
2	Experimental Autoimmune Encephalomyelitis (Encephalomyelitis, Autoimmune Experimental) 01/2021 - 01/2020
2	Hyperalgesia 01/2021 - 01/2019
2	Ulcerative Colitis 02/2019 - 04/2016
2	Type 2 Diabetes Mellitus (MODY) 01/2018 - 12/2016
1	Fibrosis (Cirrhosis) 01/2021
1	Asthma (Bronchial Asthma) 01/2021
1	Lung Diseases (Lung Disease) 01/2021
1	Neoplasms (Cancer) 01/2020
1	Multiple Sclerosis 01/2020
1	Crohn Disease (Crohn's Disease) 02/2019
1	Carcinoma (Carcinomatosis) 01/2019
1	Acute Lung Injury 01/2019
1	Edema (Dropsy) 01/2019
1	Colonic Neoplasms (Colon Cancer) 01/2019
1	Squamous Cell Carcinoma (Epidermoid Carcinoma) 01/2019
1	Pathologic Processes 01/2019
1	Carcinogenesis 12/2018
1	Atherosclerosis 03/2018
1	Neuroinflammatory Diseases 03/2018
1	Neurodegenerative Diseases (Neurodegenerative Disease) 01/2018
1	Substance-Related Disorders (Drug Abuse) 01/2018
1	Infections 09/2017
1	Bacterial Infections (Bacterial Infection) 09/2017
1	Necrosis 01/2017
1	Relapsing-Remitting Multiple Sclerosis 04/2016
1	Myalgia 04/2016
1	Erythema 04/2016
1	Glucose Intolerance 03/2015

Drug/Important Bio-Agent (IBA)

18	LipidsIBA 01/2021 - 10/2013
8	EndocannabinoidsIBA 01/2021 - 10/2012
6	N-acylethanolaminesIBA 01/2021 - 02/2015
5	EnzymesIBA 01/2021 - 08/2011
5	palmidrolIBA 01/2018 - 02/2015
4	LipopolysaccharidesIBA 01/2021 - 10/2013
4	ProstaglandinsIBA 01/2021 - 10/2013
4	CytokinesIBA 01/2021 - 10/2013
4	anandamide (arachidonylethanolamide)IBA 01/2019 - 01/2017
3	OxysterolsIBA 01/2021 - 03/2018
3	Messenger RNA (mRNA)IBA 01/2021 - 01/2019
3	InterferonsIBA 01/2019 - 04/2016
3	EstersIBA 01/2019 - 10/2013
3	Monoacylglycerol LipasesIBA 01/2019 - 08/2011
3	Dextran SulfateIBA 12/2018 - 10/2013
3	Pharmaceutical PreparationsIBA 01/2018 - 10/2013
2	AcidsIBA 01/2021 - 02/2015
2	Prostaglandin-Endoperoxide Synthases (Cyclooxygenase)IBA 01/2021 - 04/2017
2	CarrageenanIBA 01/2021 - 01/2019
2	CholesterolIBA 01/2021 - 03/2018
2	amidaseIBA 01/2021 - 02/2015
2	25-hydroxycholesterolIBA 01/2021 - 02/2019
2	glyceryl 2-arachidonate (2-arachidonoylglycerol)IBA 01/2019 - 08/2011
2	Prostaglandin D2IBA 01/2019 - 01/2018
2	Sulfonic AcidsIBA 12/2018 - 08/2011
2	Glucagon-Like Peptide 1 (GLP 1)IBA 01/2018 - 12/2016
2	LigandsIBA 01/2018 - 12/2016
2	Peroxidase (Myeloperoxidase)IBA 01/2018 - 04/2016
1	Arachidonic Acid (Vitamin F)IBA 01/2021
1	LeukotrienesIBA 01/2021
1	Flurbiprofen (Froben)FDA LinkGeneric 01/2021
1	fatty-acid amide hydrolase (fatty acid amide hydrolase)IBA 01/2021
1	Interleukin-6 (Interleukin 6)IBA 01/2020
1	MicroRNAs (MicroRNA)IBA 01/2020
1	MonoglyceridesIBA 01/2020
1	CarbenoxoloneIBA 01/2019
1	LysophospholipidsIBA 01/2019
1	carbamic acid N- methyl- N- ((3- (4- pyridinyl)phenyl)methyl)- 4'- (aminocarbonyl)(1,1'- biphenyl)- 4- yl esterIBA 01/2019
1	Capsaicin (Zostrix)FDA Link 01/2019
1	HydrolasesIBA 01/2019
1	EndotoxinsIBA 01/2019
1	lysophosphatidylinositolIBA 12/2018
1	activin AIBA 01/2018
1	prostaglandin R2 D-isomerase (prostaglandin D2 synthase)IBA 01/2018
1	N-oleoylethanolamineIBA 01/2018
1	Neuroprotective AgentsIBA 01/2018
1	Cyclooxygenase 2 (Cyclooxygenase-2)IBA 01/2018
1	Toll-Like Receptor 4IBA 11/2017
1	Dinoprostone (PGE2)FDA Link 09/2017
1	AntigensIBA 09/2017
1	Anti-Inflammatory Agents (Anti-Inflammatories)IBA 04/2017
1	CurcuminIBA 07/2016
1	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 04/2016
1	Immunosuppressive Agents (Immunosuppressants)IBA 04/2016
1	Dextrans (Dextran)FDA Link 04/2016
1	Cyclosporine (Ciclosporin)FDA LinkGeneric 04/2016
1	Lipid NanoparticlesIBA 04/2016
1	sodium sulfate (sodium bisulfate)FDA LinkGeneric 04/2016
1	SteroidsIBA 04/2016
1	1-dodecylpyridoxal (PLD)IBA 03/2015

Therapy/Procedure

2	Therapeutics 04/2016 - 04/2016
1	Traditional Medicine (Folk Remedies) 01/2022
1	Intranasal Administration 01/2021
1	Oral Administration 04/2016